Human recombinant interleukin-1 beta-mediated growth inhibition of cultured malignant glioma cells.
The effect of human recombinant interleukin-1 beta (hrIL-1 beta) on tumor growth was studied in eight glioma cell lines. hrIL-1 beta inhibited growth in all cell lines, but to varying extents. Two cell lines were suppressed by 0.5 ng/ml hrIL-1 beta, and three cell lines required 20 ng/ml. hrIL-1 beta also induced morphological changes and increased F-actin contents. hrIL-1 beta-treated cells demonstrated multipolar shapes and numerous processes with a greater number of cell-cell contacts 24 hours after treatment. Fluorescence microscopy revealed that these processes contained a large amount of polymerized F-actin. These results suggest that hrIL-1 beta-mediated growth inhibition may be related to the differentiation of glioma cells.
Koga
H
H
Department of Neurosurgery, University of the Ryukyus School of Medicine, Okinawa.
Mukawa
J
J
Miyagi
K
K
Higa
Y
Y
Nakasone
S
S
Mekaru
S
S
Ingram
M
M
D001932:Brain Neoplasms / Q000276:immunology / Q000473:pathology*; D002455:Cell Division / Q000187:drug effects; D005260:Female; D005434:Flow Cytometry; D005910:Glioma / Q000276:immunology / Q000473:pathology*; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology*; D008297:Male; D008856:Microscopy, Fluorescence; D014407:Tumor Cells, Cultured / Q000187:drug effects
D007375:Interleukin-1